We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
Cap. Flow
+$552M
Cap. Flow %
5.91%
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$50.3M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$39.4M
3
INTC icon
Intel
INTC
+$29.2M
4
QCOM icon
Qualcomm
QCOM
+$27.6M
5
DHR icon
Danaher
DHR
+$26M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$49.9M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$41.6M
3
ARQL
Arqule Inc
ARQL
+$26.5M
4
ARWR icon
Arrowhead Research
ARWR
+$24.9M
5
MRK icon
Merck
MRK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 30.73%
2 Technology 19.55%
3 Financials 10.18%
4 Consumer Discretionary 9.32%
5 Communication Services 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CL icon
201
Colgate-Palmolive
CL
$72.6B
$10.8M 0.12%
157,226
+5,059
+3% +$345K
SAGE
202
DELISTED
Sage Therapeutics
SAGE
$10.8M 0.12%
149,300
+10,000
+7% +$1.23M
EXAS
203
DELISTED
Exact Sciences
EXAS
$10.8M 0.12%
116,332
+61,690
+113% +$5.42M
TGTX icon
204
TG Therapeutics
TGTX
$8.58B
$10.7M 0.11%
+959,916
New +$7.3M
ZGNX
205
DELISTED
Zogenix, Inc.
ZGNX
$10.6M 0.11%
203,700
-67,000
-25% -$3.07M
ZYME icon
206
Zymeworks
ZYME
$1.68B
$10.6M 0.11%
+232,255
New +$8.44M
AMBA icon
207
Ambarella
AMBA
$2.99B
$10.6M 0.11%
174,323
+40,646
+30% +$2.25M
CLVS
208
DELISTED
Clovis Oncology, Inc.
CLVS
$10.4M 0.11%
999,853
-131,270
-12% -$955K
GPRK icon
209
GeoPark
GPRK
$649M
$10.3M 0.11%
468,868
+119,476
+34% +$2.27M
BHVN
210
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.3M 0.11%
188,799
-231,000
-55% -$11.4M
RTX icon
211
RTX Corp
RTX
$287B
$10.2M 0.11%
107,822
-2,695
-2% -$244K
OKE icon
212
Oneok
OKE
$58.7B
$10.1M 0.11%
133,393
+25,535
+24% +$1.83M
LNC icon
213
Lincoln National
LNC
$7.91B
$10M 0.11%
170,044
+19,485
+13% +$1.15M
KYNB
214
Kyntra Bio
KYNB
$28.5M
$9.93M 0.11%
9,256
-10,260
-53% -$10.5M
TD icon
215
Toronto Dominion Bank
TD
$198B
$9.9M 0.11%
176,351
+16,553
+10% +$939K
ANET icon
216
Arista Networks
ANET
$219B
$9.9M 0.11%
778,768
-74,448
-9% -$979K
EIDX
217
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$9.86M 0.11%
171,755
-47,245
-22% -$2.34M
ZBH icon
218
Zimmer Biomet
ZBH
$17.7B
$9.71M 0.1%
66,838
-13,707
-17% -$1.89M
RF icon
219
Regions Financial
RF
$26.3B
$9.67M 0.1%
563,711
+33,080
+6% +$545K
WMB icon
220
Williams Companies
WMB
$90.5B
$9.58M 0.1%
403,865
+61,762
+18% +$1.41M
GTHX
221
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$9.53M 0.1%
360,387
+57,887
+19% +$1.35M
TPTX
222
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$9.51M 0.1%
152,628
+119,628
+363% +$5.69M
GM icon
223
General Motors
GM
$74.7B
$9.4M 0.1%
256,887
+129,689
+102% +$4.71M
HST icon
224
Host Hotels & Resorts
HST
$16.8B
$9.4M 0.1%
506,601
+128,251
+34% +$2.22M
COR icon
225
Cencora
COR
$60.3B
$9.38M 0.1%
110,339
-14,448
-12% -$1.24M
7 8
9
10 11

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2019 Portfolio in Review

As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.

  • Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
  • Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
  • Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
  • Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
  • Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
  • Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
  • Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.